February Emerging Medical Technologies Report

Published January 2012 | 95 Pages | 43 Exhibits |


Order individually or subscribe and get a complete intel platform.


This report includes details on 43 emerging medical technology companies that have been identified by LSI's in-house research team in February 2012.

All companies include technology, market(s), key executive, and contact information.

Two- to three-page executive summaries are provided on most of the companies. Executive summaries typically include:

• Company Contact Information
• Company Overview (structure, size, year founded, etc.)
• Competitive Landscape
• Technological Advantage
• Stage of Development
• Target Markets
• Financial Summary and Sales Forecasts
• Financing & Partnering Needs
• IP Position & Status
• Management Team
• Exit Strategy
• More

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents

• 1-A proprietary non-invasive ophthalmic diagnostic device designed to quickly detect elevated advanced glycosolated end products (AGEs) for very early detection of diabetes and 2-A rapid non-invasive, ophthalmic-based glucometer for painless and convenient measurement of glucose levels
• A light-based medical device in the form of an LED patch with a proprietary, optimized formulation of light which triggers local, controllable, and safe Nitric Oxide (NO) production to treat diseases triggered by underlying vascular dysfunction
• A pioneering ozone-oxygen-vacuum system for healing chronic, hard-to-heal wounds. The technology is non-invasive and medically proven for diabetic foot, PVD, venous ulcers, and more.
• A unique, simple-to-use, single-use inhaler device to address major unmet needs in the respiratory and drug-delivery fields; specifically, the acute treatment of asthma and COPD
• An innovative enabling platform technology that harvests tens of millions of a patient's own adipose-derived regenerative cells in one hour, for immediate application
• Antalgic-Trak(R) (A-T) is the only non-surgical spinal decompression system in the world engineered with a series of multi-axis articulating sections that provide and create spinal "Range-Of-Motion" (ROM) therapy
• Cosmetic and drug delivery systems based on nanotechnology
• Disposable medical device to improve stroke risk during heart bypass procedures
• EpiLert is a wireless, watch-like device providing real-time ALERT to CAREGIVERS of an ongoing epileptic seizure
• Expanding hydraulic implant for use in lumbar spinal fusion procedures
• High-quality low-cost spine implants
• ICDR, a simple yet sophisticated Internal Cavity Drug Retention system for controlled and highly effective delivery of therapeutic agents into the bladder. Based on advanced materials technologies, the ICDR system improves drug bioavailability and reduces toxicity, significantly enhancing treatment potential, safety, and compliance.
• Innovative antibiofilm catheter lock technology to reduce infection associated with indwelling catheters
• Innovative therapies utilizing pepducins to modulate G-protein receptors, thereby expanding treatments for cancer, diabetes, inflammation, and regenerative medicine
• Innovative ultra-sensitive immunodiagnostic systems for use in research and in-vitro diagnostics
• Innovative, implantable, combination drug+device products that utilize novel biomaterials. TYRX's first commercially available products include the AIGISRx(R) Antibacterial Envelope & Flat Sheet technologies, designed to reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs).
• Next generation G-protein coupled receptor-biased ligand pharmaceuticals which are intended to limit adverse drug effects
• Next-generation non-invasive portable ultrasound system for the treatment of fat, skin, and other plastic surgery and dermatology applications at all anatomical sites - without anesthesia and surgery
• Next-generation prefilled drug delivery devices, including prefilled syringes, auto-injectors, and IV systems, offering improved product performance at lower costs
• Novel biotherapeutic technologies featuring self-contained subcutaneous delivery mechanisms
• Novel diagnostics utilizing protein based biomarker technology focused on nosocomial disease
• Novel ophthalmic therapies to treat ocular diseases
• Novel small molecule therapies for respiratory disorders
• Novel thyroid FNA analysis technology combines cytopathology and Afirma Gene Expression Classifier for nodule assessment
• Novel, POC diagnostic instrument that rapidly diagnoses blood coagulation defects based on sonorheometry - a patented ultrasound-based technology that is faster, easier to operate and interpret, and cheaper than competing technologies
• Patient-specific epigenetic therapeutics utilizing small molecule histone methyltransferase (HMT) inhibitors for the treatment of cancer
• PediGuard is the world's first and only hand-held device capable of alerting surgeons to potential pedicular or vertebral breaches. Real-time feedback is provided via audio and visual signals.
• Proprietary implant technology featuring a hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea
• Proprietary, non-fusion spinal motion preservative total disc replacement technology (ErgoFlex) that provides permanent solutions for lower back (lumbar) area disc problems. The technology is easily adaptable to the entire spine and the company's next target area is the neck (cervical).
• Resin-based vehicles that quickly deliver medications transmucosally to the bloodstream and formulations that treat such conditions as smoking cessation, anxiety, chronic breakthrough pain, and migraines
• Self-adjustable vaginal ring pessary to treat urinary incontinence and genital prolapse without drugs
• Targeted oral therapeutics to correct mineral metabolism and metabolic disorders
• The BNX(TM) (Beacon-Needle-eXchange) needle delivery system for use in gastrointestinal endoscopic procedures including: Endoscopic Ultrasound (EUS), Endoscopic Bronchial Ultrasound (EBUS), and Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
• The Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI/MBI - a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake
• The DISTALOCK Intramedullary Nail and Drill System uses an innovative approach to facilitate the accurate placement of locking screws used to stabilize the rod-like implants, or nails, used for long bone fractures
• The Extremity Compartment Syndrome (ECS) System is being launched as the only FDA-cleared continuous monitoring device that assists physicians with diagnosing a limb-threatening complication
• The first tomographic, real-time, high-resolution imaging system for pulmonary disease management. The Tomophase OCTIS(TM) is being deployed in major hospitals worldwide.
• The Superion Interspinous Spacer system is the most advanced and least invasive spacer system and is delivered through a percutaneous midline approach for the treatment of lumbar spinal stenosis
• The Unyvero(TM) System is a novel high-multiplex MDx/IVD platform for severe infectious disease (Pneumonia Application has 39 analytes: 17 pathogens, 22 antibiotic resistance markers)
• The VortxRX delivers non-invasive Histotripsy with image guidance to treat benign prostatic hyperplasia (BPH). Histotripsy homogenizes prostatic tissue non-thermally as it is monitored in real time with ultrasound imaging.
• Therapeutics based on natural killer cells (NKT), a subset of immune cells, intended for the treatment of autoimmune and inflammatory diseases in addition to asthma, cancer, and dermatitis
• Therapeutics for the treatment of post-operative and chronic pain
• Unique solutions for ophthalmic conditions such as: presbyopia, myopic progression using contact lenses, intraocular lenses and lasik, or other corneal surgeries

Ready to get started?

Our trusted team is here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media. Get in touch today.